Antipsychotic-induced hyperprolactinaemia, hypogonadism and osteoporosis in the treatment of schizophrenia
- 1 March 2008
- journal article
- review article
- Published by SAGE Publications in Journal of Psychopharmacology
- Vol. 22 (2_suppl) , 70-75
Abstract
Treatment of schizophrenic illness usually involves the long-term administration of antipsychotic drugs. Most antipsychotic agents antagonise the actions of endogenous dopamine (DA) at DA-2 receptors in the brain. The relative affinity for, and binding time to, DA-2 receptors was considered to be one of the key determinants of the antipsychotic potency of classical antipsychotic drugs. Some newer atypical antipsychotics, of which clozapine is the prototype, have a relatively poor affinity for DA-2 receptors; whereas other atypical antipsychotics are potent DA-2 antagonists. The propensity of antipsychotic agents to cause hyperprolactinaemia is related to their potency in antagonising DA-2 receptors on the anterior pituitary. In our studies, bone loss was consistently related to DA-2 antagonist potency of antipsychotic drugs, rather than their classification using conventional `typical' versus `atypical' systems. It is established that hyperprolactinaemia causes suppression of the reproductive endocrine axis and consequent bone mineral density (BMD) loss. Results from our group and others have demonstrated that a similar pathophysiological process is occurring in individuals with antipsychotic-induced hyperprolactinaemia. We found high rates of osteoporosis and osteopenia in those taking long-term antipsychotic drugs, and this was related to the dose and duration of treatment. Bone loss was associated with hypogonadism in male and female groups. Young Caucasian women appear to be particularly vulnerable to developing hyperprolactinaemia and the associated hypogonadism and bone loss. The occurrence of menstrual dysfunction should alert clinical suspicions of hyperprolactinaemia and bone de-mineralisation. Lastly, there are no published trials examining the effects of hormone replacement on BMD in those taking long-term antipsychotic drugs, but preliminary findings from our studies suggest that active management of bone loss in those with antipsychotic-associated bone disease may halt or even reverse this process.Keywords
This publication has 23 references indexed in Scilit:
- Categorical prevalence and severity of hyperprolactinaemia in two UK cohorts of patients with severe mental illness during treatment with antipsychoticsJournal of Psychopharmacology, 2008
- Prolactin and dopamine: What is the connection? A Review ArticleJournal of Psychopharmacology, 2008
- Medical causes and consequences of hyperprolactinaemia. A context for psychiatristsJournal of Psychopharmacology, 2008
- Bone Mineral Density and Its Relationship to Prolactin Levels in Patients Taking Antipsychotic TreatmentJournal of Clinical Psychopharmacology, 2005
- Sex hormones in psychotic menPsychoneuroendocrinology, 2005
- Effects of Elevated Serum Prolactin on Bone Mineral Density and Bone Metabolism in Female Patients With Schizophrenia: A Prospective StudyAmerican Journal of Psychiatry, 2003
- Risperidone, but Not Olanzapine, Decreases Bone Mineral Density in Female Premenopausal Schizophrenia PatientsThe Journal of Clinical Psychiatry, 2003
- CLASSICAL AND ATYPICAL NEUROLEPTICS, AND BONE MINERAL DENSITY, IN PATIENTS WITH SCHIZOPHRENIAInternational Journal of Neuroscience, 2002
- Accelerated Osteoporosis in Psychiatric Patients: Possible Pathophysiological ProcessesSchizophrenia Bulletin, 1996
- Oral progestogen‐only contraception may protect against loss of bone mass in breast‐feeding womenClinical Endocrinology, 1994